ABO Blood Type and Pretreatment Systemic Inflammatory Response Index Associated with Lymph Node Metastasis in Patients with Breast Cancer

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2024 Oct 28

PMID 39465189

Authors

Nating Xiong

Wendao Han

Zhikang Yu

Affiliations

Soon will be listed here.

Abstract

Background: Lymph node metastasis (LNM) is an important prognostic factor for breast cancer. Inflammatory stimulation can change tumor microenvironment and lead to LNM, but the relationship between LNM and peripheral immunoinflammatory indices has not been clarified in breast cancer.

Methods: The clinical information of 1918 patients with breast cancer admitted to Meizhou People's Hospital from October 2017 to December 2023 were retrospectively analyzed. The relationship of clinicopathological features (age, body mass index (BMI), ABO blood types, family history of cancer, tumor site, disease stage, LNM, distant metastasis, and molecular subtypes) and peripheral immunoinflammatory indices (pan-immune inflammation value (PIV), systemic immune inflammation index (SII), and system inflammation response index (SIRI)) were analyzed.

Results: There were 935 (48.7%) patients had no LNM and 983 (51.3%) had LNM. There were statistically significant differences in the distributions of ABO blood groups (=0.022) and molecular subtypes (<0.001) between the two groups. PIV, SII, and SIRI levels in patients with LNM were significantly higher than those without LNM (all <0.05). The proportions of LNM in patients with high PIV, SII, and SIRI levels were higher than those with low PIV, SII, and SIRI levels, respectively. Logistic regression analysis showed that non-O blood type (non-O blood type vs O blood type, odds ratio (OR): 1.327, 95% confidence interval (CI): 1.056-1.667, =0.015), luminal B subtype (luminal B vs luminal A, OR: 2.939, 95% CI: 2.147-4.022, <0.001), HER2+ subtype (HER2+ vs luminal A, OR: 2.044, 95% CI: 1.388-3.009, <0.001), and high SIRI level (≥0.875 vs <0.875, OR: 1.572, 95% CI: 1.092-2.265, =0.015) were independently associated with LNM.

Conclusion: Non-O blood type, luminal B and HER2+ subtypes, and high SIRI level (≥0.875) have potential role in predicting the status of LNM in breast cancer patients.

Citing Articles

Evaluation of placental growth factor, Vitamin D, and systemic inflammatory index as predictive biomarkers for preeclampsia severity: a retrospective cohort study.

Han X, Yang H BMC Pregnancy Childbirth. 2025; 25(1):75.

PMID: 39871211 PMC: 11771059. DOI: 10.1186/s12884-025-07187-x.

References

Kidane D, Chae W, Czochor J, Eckert K, Glazer P, Bothwell A . Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol. 2014; 49(2):116-39. PMC: 4300235. DOI: 10.3109/10409238.2013.875514. View

Eastlund T . The histo-blood group ABO system and tissue transplantation. Transfusion. 1998; 38(10):975-88. DOI: 10.1046/j.1537-2995.1998.381098440863.x. View

Candido J, Hagemann T . Cancer-related inflammation. J Clin Immunol. 2012; 33 Suppl 1:S79-84. DOI: 10.1007/s10875-012-9847-0. View

Hakomori S . Antigen structure and genetic basis of histo-blood groups A, B and O: their changes associated with human cancer. Biochim Biophys Acta. 1999; 1473(1):247-66. DOI: 10.1016/s0304-4165(99)00183-x. View

Min S, Lee S, Woo J, Jung S, Ryu J, Yu J . Relation Between Tumor Size and Lymph Node Metastasis According to Subtypes of Breast Cancer. J Breast Cancer. 2021; 24(1):75-84. PMC: 7920868. DOI: 10.4048/jbc.2021.24.e4. View

Bodogai M, Moritoh K, Lee-Chang C, Hollander C, Sherman-Baust C, Wersto R . Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. Cancer Res. 2015; 75(17):3456-65. PMC: 4558269. DOI: 10.1158/0008-5472.CAN-14-3077. View

Hakomori S . Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol. 2003; 491:369-402. DOI: 10.1007/978-1-4615-1267-7_24. View

Nielsen S, Schmid M . Macrophages as Key Drivers of Cancer Progression and Metastasis. Mediators Inflamm. 2017; 2017:9624760. PMC: 5292164. DOI: 10.1155/2017/9624760. View

Bertsch T, Ludecke J, Antl W, Nausch L . Karl Landsteiner: The Discovery of the ABO Blood Group System and its Value for Teaching Medical Students. Clin Lab. 2019; 65(6). DOI: 10.7754/Clin.Lab.2018.181218. View

10.

Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J . Systemic Immune Inflammation Index (SII), System Inflammation Response Index (SIRI) and Risk of All-Cause Mortality and Cardiovascular Mortality: A 20-Year Follow-Up Cohort Study of 42,875 US Adults. J Clin Med. 2023; 12(3). PMC: 9918056. DOI: 10.3390/jcm12031128. View

11.

Pereira A, Siegrist J, Lizarraga S, Perez-Medina T . Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement. J Pers Med. 2022; 12(9). PMC: 9505126. DOI: 10.3390/jpm12091404. View

12.

Liu Y, Ge J, Chen Y, Liu T, Chen L, Liu C . Combined Single-Cell and Spatial Transcriptomics Reveal the Metabolic Evolvement of Breast Cancer during Early Dissemination. Adv Sci (Weinh). 2023; 10(6):e2205395. PMC: 9951304. DOI: 10.1002/advs.202205395. View

13.

Chen L, Kong X, Wang Z, Wang X, Fang Y, Wang J . Pretreatment Systemic Inflammation Response Index in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator. Cancer Manag Res. 2020; 12:1543-1567. PMC: 7060771. DOI: 10.2147/CMAR.S235519. View

14.

Cao X, Wen Z, Sun Y, Li Y, Zhang L, Han Y . Prognostic value of ABO blood group in patients with surgically resected colon cancer. Br J Cancer. 2014; 111(1):174-80. PMC: 4090745. DOI: 10.1038/bjc.2014.302. View

15.

He W, Li Q, Yang M, Jiao J, Ma X, Zhou Y . Lower BMI cutoffs to define overweight and obesity in China. Obesity (Silver Spring). 2015; 23(3):684-91. DOI: 10.1002/oby.20995. View

16.

Liu Q, Sun H, Yang X, Chen M, Liu Y, Zhao Y . Survival following radiotherapy in young women with localized early-stage breast cancer according to molecular subtypes. Cancer Med. 2019; 8(6):2840-2857. PMC: 6558475. DOI: 10.1002/cam4.2186. View

17.

Gates M, Xu M, Chen W, Kraft P, Hankinson S, Wolpin B . ABO blood group and breast cancer incidence and survival. Int J Cancer. 2011; 130(9):2129-37. PMC: 3655700. DOI: 10.1002/ijc.26220. View

18.

Si C, Jin Y, Wang H, Zou Q . Association between molecular subtypes and lymph node status in invasive breast cancer. Int J Clin Exp Pathol. 2014; 7(10):6800-6. PMC: 4230091. View

19.

Dogan I, Ayhan M, Gurbuz M, Kucukarda A, Aydin E, Urun Y . The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study. Medicine (Baltimore). 2022; 101(35):e30147. PMC: 9439766. DOI: 10.1097/MD.0000000000030147. View

20.

Varol C, Mildner A, Jung S . Macrophages: development and tissue specialization. Annu Rev Immunol. 2015; 33:643-75. DOI: 10.1146/annurev-immunol-032414-112220. View